The TIDY HF analyzed the implementation of medical therapy in de novo heart failure with reduced ejection fraction and found that at 3 months of follow-up, 91.4% of patients were treated with SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and heart failure.